Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 1674-1676, September 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vesselinovitch, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vesselinovitch, S. D.

The Strain Difference in the Induction of Leukemia by Urethan1

S. D. Vesselinovitch2

Division of Oncology, The Chicago Medical School, Institute for Medical Research, Chicago, Illinois 60612

The objective of the present investigation was to find out the trends in leukemogenesis in several strains of mice when exposed to identical, leukemogenic, urethan treatments.

C3H, C57BL, and (C57BL x C3H)F1 mice were exposed to repeated i.p. injections of urethan. The injections were given at 3-day intervals, the first when mice were less than 24 hours of age. Animals received either 3 or 6 treatments (0.7 mg/gm body weight each) totaling 2.1 or 4.2 mg of urethan per gram body weight. The experiment terminated when the mice were 40 weeks of age.

All three strains developed leukemia, although in different incidences. The C57BL were most responsive (49% and 82% for two dose levels), while C3H were the least responsive (12% and 52% for two dose levels). Their F1 hybrids developed leukemia in an intermediate fashion.

Several factors which might be associated with the strain difference in the development of leukemia are discussed.

1 This investigation was supported by Contract PH 43-65-67 from the National Cancer Institute, NIH, USPHS.

2 Present address: Department of Radiology, The University of Chicago, Chicago, Illinois 60637.

Received 10/16/68. Accepted 5/ 8/68.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.